Corning Incorporated Introduces New Synthemax™ Synthetic Surface to Enhance and Support Stem Cell Growth
03 Março 2010 - 6:30PM
Business Wire
Corning Incorporated (NYSE:GLW) today introduced the Corning®
Synthemax™ surface, a novel synthetic surface that supports the
growth and differentiation of stem cells. The surface is being
commercialized as a result of Corning’s ongoing collaboration with
Geron Corporation (NASDAQ:GERN). This development enables
researchers to take the next step toward scalable and
cost-effective manufacturing of stem cells for potential therapies
in the treatment of degenerative diseases.
Data presented by Corning and Geron at the World Stem Cell
Summit in Baltimore in September 2009 demonstrated multi-passage
growth of multiple undifferentiated human stem cell lines and the
subsequent differentiation of one of these cell lines into
cardiomyocytes. This is the first time the differentiation has been
demonstrated with the results presented on a synthetic surface. The
growth and differentiation of stem cells on the Synthemax surface
is robust and reproducible, an important condition for the
large-scale production of cells and therapeutic development.
“The commercialization of the Synthemax surface is a clear proof
point of the success of our collaboration with Geron,” said Dr.
Jeff Mooney, director of commercial technology for Corning Life
Sciences. “By leveraging our unique expertise in materials and
surfaces, as well as Geron’s advanced therapeutic stem cell
techniques, we have been able to develop what we believe is the
first and only synthetic surface in the world to enable this level
of stem cell growth and differentiation.”
The Corning Synthemax surface allows for the scalable expansion
of stem cells for more than 20 serial passages in a defined
xeno-free medium with:
- Stable doubling time;
- Phenotypic marker expression
(Oct4, TRA-1-60, SSEA4);
- Retention of normal karyotype;
and
- Maintenance of
pluripotency.
Since 2006, Corning has worked with Geron to develop synthetic
surface matrices to support the scalable manufacturing of stem
cells and derived differentiated cell types (e.g., cardiomyocytes).
Synthetic growth surfaces could replace the biological surface
coatings that are widely used today to grow and differentiate
pluripotent stem cells and may offer increased reproducibility,
cost savings, and regulatory advantages.
Laboratory products using specialized surfaces, such as the
Synthemax surface, are being commercialized by Corning. Currently,
Corning’s six-well plate with the Corning Synthemax surface is
available in North America.
Corning Life Sciences brings new and innovative laboratory
technologies to researchers worldwide and helps customers succeed
by providing innovative, high-quality products and services in the
areas of polymer science, biochemistry and molecular biology, glass
melting and forming, surface modification, and characterization
science.
For additional information on the new Corning Synthemax surface
or any other Corning Life Sciences products, please contact a
customer service representative at 1-800-492-1110, toll free in the
United States, (+1) 1-978-442-2200 internationally, or visit
www.corning.com/lifesciences.
Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within
the meaning of the Private Securities Litigation Reform Act of
1995), which are based on current expectations and assumptions
about Corning’s financial results and business operations, that
involve substantial risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties
include: the effect of global political, economic and business
conditions; conditions in the financial and credit
markets; currency fluctuations; tax rates; product demand
and industry capacity; competition; reliance on a concentrated
customer base; manufacturing efficiencies; cost reductions;
availability of critical components and materials; new product
commercialization; pricing fluctuations and changes
in the mix of sales between premium and non-premium
products; new plant start-up or restructuring costs;
possible disruption in commercial activities due to terrorist
activity, armed conflict, political instability or major health
concerns; adequacy of insurance; equity company activities;
acquisition and divestiture activities; the level of excess or
obsolete inventory; the rate of technology change; the ability to
enforce patents; product and components performance issues; stock
price fluctuations; and adverse litigation or regulatory
developments. These and other risk factors
are detailed in Corning’s filings with the Securities and
Exchange Commission. Forward-looking statements speak only as
of the day that they are made, and Corning undertakes no obligation
to update them in light of new information or future events.
About Corning Incorporated
Corning Incorporated (www.corning.com) is the world leader in
specialty glass and ceramics. Drawing on more than 150 years of
materials science and process engineering knowledge, Corning
creates and makes keystone components that enable high-technology
systems for consumer electronics, mobile emissions control,
telecommunications and life sciences. Our products include glass
substrates for LCD televisions, computer monitors and laptops;
ceramic substrates and filters for mobile emission control systems;
optical fiber, cable, hardware & equipment for
telecommunications networks; optical biosensors for drug discovery;
and other advanced optics and specialty glass solutions for a
number of industries including semiconductor, aerospace, defense,
astronomy and metrology.
Geron Safe Harbor
This news release may contain forward-looking statements made
pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release regarding potential applications
of Geron’s human embryonic stem cell technology constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of Geron’s intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect Geron’s results and other risks and uncertainties are
detailed from time to time in Geron’s periodic reports including
the annual report on Form 10-K for the year ended December 31,
2009.
About Geron Corporation
Geron is developing first-in-class biopharmaceuticals for the
treatment of cancer and chronic degenerative diseases, including
spinal cord injury, heart failure and diabetes. The company is
advancing an anti-cancer drug and a cancer vaccine that target the
enzyme telomerase through multiple clinical trials in different
cancers. For more information, visit www.geron.com.
Corning (NYSE:GLW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Corning (NYSE:GLW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024